Spectral AI (MDAI) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spectral AI (MDAI) has outperformed Nephros (NEPH) over the past year, losing 27.3% versus a loss of 46.4%. Over five years, NEPH leads with a -63.6% price change compared with -89.5% for MDAI. Spectral AI is the larger company by market cap ($33.5 million vs $28.4 million), about 1.2 times the size, while Nephros is growing revenue faster (+32.7% vs -33.6%).
Nephros converts more of its revenue into profit, with a net margin of 6.4% versus -38.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDAI | NEPH |
|---|---|---|
| Share price | $1.04 | $2.61 |
| Market cap | $33.47M | $28.37M |
| 1-day change | -20.61% | -8.10% |
| YTD return | -26.76% | -46.52% |
| 1-year return | -27.27% | -46.41% |
| 5-year return | -89.45% | -63.60% |
| P/E ratio (TTM) | — | 15.35 |
| Forward P/E | — | 11.86 |
| EPS (TTM) | $-0.30 | $0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.65M | $18.79M |
| Revenue growth (YoY) | -33.57% | +32.67% |
| Net income (latest FY) | $-7.57M | $1.19M |
| Gross margin | 45.42% | 61.87% |
| Operating margin | -43.78% | 6.10% |
| Net margin | -38.53% | 6.35% |
| 52-week high | $2.97 | $6.42 |
| 52-week low | $1.00 | $2.61 |
| Distance from 52-week high | -64.98% | -59.35% |
| Analyst consensus | none | none |
| Avg. price target upside | +391.35% | +139.46% |
| Average volume | 142.00K | 48.33K |
| Shares outstanding | 32.18M | 10.87M |
| Employees | 65 | 36 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDAI has outperformed NEPH by 19.1 percentage points over the past year.
- Nephros is more profitable, keeping 6.4 cents of every revenue dollar as net income versus -38.5 cents for Spectral AI.
- Nephros grew revenue faster in its latest fiscal year (+32.67% vs -33.57%).
About Spectral AI
MDAI stock →Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds.
Health Care · Medical/Dental Instruments · 65 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
MDAI vs NEPH FAQ
Which is bigger, Spectral AI or Nephros?
Spectral AI (MDAI) is larger, with a market capitalization of $33.47M compared with $28.37M for Nephros (NEPH).
Which stock has performed better over the past year, MDAI or NEPH?
MDAI returned -27.27% over the past 12 months, compared with -46.41% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Are Spectral AI and Nephros in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.